Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.39 |
| ▸ | CPB1 | P15086 | 5/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2282033 | 0.85 | CPB2 (0.45) | MEN1KMT2AGRM2CPB2CPB1 | |
| SCHEMBL20857112 | 0.84 | NOTUM (0.47) | MEN1KMT2ACPB2CPB1 | |
| SCHEMBL21361934 | 0.84 | MEN1 (0.43) | MEN1KMT2AGRM2CPB2SMYD3 | |
| SCHEMBL26813648 | 0.83 | CPB2 (0.42) | MEN1KMT2AGRM2CPB2CPB1 | |
| SCHEMBL26813651 | 0.83 | CPB2 (0.45) | MEN1KMT2AGRM2CPB2CPB1 | |
| SCHEMBL20139133 | 0.83 | MEN1 (0.42) | MEN1KMT2AGRM2CPB2SMYD3 | |
| SCHEMBL7425205 | 0.81 | SMYD3 (0.50) | MEN1KMT2AGRM2CPB2SMYD3 | |
| SCHEMBL5726708 | 0.81 | CPB2 (0.45) | MEN1KMT2AGRM2CPB2CPB1 | |
| SCHEMBL28579686 | 0.81 | MEN1 (0.41) | MEN1KMT2AGRM2CPB2CPB1 | |
| SCHEMBL26641301 | 0.81 | KDM5A (0.47) | MEN1KMT2AGRM2SMYD3ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299143-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-22 | — | — | US | disclosed |
| EP-2925746-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014086663-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299143-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | HDAC7, PSMB7, IKZF3 | MEN1 2978/4885KMT2A 875/4885GRM2 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.